18F-氟赤硝基咪唑PET-CT检测非小细胞肺癌乏氧的应用价值

Objective To assess the feasibility of [18F ] fluoroerythronitroimidazole (18F-FETNIM ) with integrated positron emission tomography and computed tomography (PET-CT) imaging in detection of hypoxia in non-small-cell lung cancer ( NSCLC) patients. Methods Forty-two patients with newly diagnosed NSCLC underwent 18F-FETNIM PET-CT before treatment. Nineteen patients rested for approximately 120 minutes before undergoing PET-CT,23 patients underwent 2 sequential PET-CT scans at 60 minutes and 120 minutes after intravenous injection 18F-FETNIM. 18F-FETNIM uptake was quantified by calculating the maximum standardized uptake value in the tumor (SUVmax-T) and contralateral normal lung tissue (SUVmax-N). Regions of interest (ROIs) were drawn in the tumor and contralateral position and the radioactivity ratio of tumor to normal (T/N) was calculated.Results SUVmax-T ( 2. 43 ± 1. 34) was significantly higher than SUVmax-N (0.87 ±0.46, P<0.001) at 120 min. SUVmax-T (2. 80 ± 1.09) and SUVmax-N (1. 16 ± 0. 56) at 60 min were significantly higher than SUVmax-T (2. 61 ± 1. 10) and SUVmax-N (P<0.01) at 120 min. T/N (2.56 ± 0.71) at 60 min was higher than that at 120 min (2.48 ± 0.60),but the difference between them was not significant (P =0.324). Conclusion Our results indicate that 18F-FETNIM PET-CT may be a useful tool for evaluating hypoxia and may be a means to target specifically tumor cells resistant to conventional treatment before and during ongoing therapy in NSCLC.

Value of 18F-FETNIM PET-CT for detection of tumor hypoxia in non-small-cell lung cancer